Tykerb
(lapatinib)Phase 3Small molecule
GSKLapatinib is used to treat certain types of breast cancer by blocking proteins that help cancer cells grow and survive.[1] Tykerb is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Tykerb is one of 136 small molecule programs targeting Breast Neoplasm. It is currently in Phase 3.
7
Indications
158
Total Trials
5
Active Trials
135
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
71 competitors in Breast Neoplasm
#DrugCompanyPhaseTrials
1Tykerb
GSKPhase 3
Fotivda
RocheApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Calciferol
Jazz PharmaceuticalsApproved
Lenvima
EisaiApproved
Venclexta
AbbVieApproved
Truqap
AstraZenecaApproved
Zometa
PfizerApproved
Tukysa
PfizerApproved
Eloxatin
TevaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer80 trials
Show 77 more trials
Lapatinib and Circulating Tumor Cells in Breast Cancer
Completed·—·Phase 2·NCT00694252·20 enrolled
ErbB2 Positive Metastatic Breast Cancer
Terminated·—·Phase 1/2·NCT01658358·15 enrolled
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
Terminated·—·Phase 2·NCT00754702·16 enrolled
Apatinib7 trials
Show 4 more trials
Gastric Cancer5 trials
Head and Neck Cancer4 trials
54 more indications
Ependymoma2 trials
Solid Tumors2 trials
Squamous Cell Carcinoma2 trials
Vinorelbine2 trials
Endocrine Therapy2 trials
Colorectal Cancer2 trials
Targeted Therapy1 trial
Intravenous1 trial
Advanced Solid Tumor1 trial
Peritoneal Cancer1 trial
Refractory1 trial
Bladder Carcinoma1 trial
Advanced Solid Malignancies1 trial
Cervical Cancer1 trial
Locally Advanced Head and Neck Cancer1 trial
Adenocarcinoma1 trial
Neoadjuvant Treatment1 trial
Malignant Glioma1 trial
Esophageal Cancer1 trial
Pituitary Tumor1 trial
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Completed·—·Phase 2·NCT00939523·9 enrolled
End-Stage Renal Disease1 trial
Glioma1 trial
Advanced Solid Tumor Cancer1 trial
Ovarian Cancer1 trial
Gallbladder Carcinoma1 trial
Primary Peritoneal Cancer1 trial
Patients With Solid Tumors1 trial
Non-Small Cell Lung Cancer1 trial
Chemotherapy1 trial
Advanced Cancer1 trial
Monotherapy1 trial
Ductal Carcinoma in Situ1 trial
Carboplatin1 trial
Thyroid Cancer1 trial
Brain Metastases1 trial
Surgery1 trial
Immunotherapy1 trial
Vestibular schwannoma1 trial
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00863122·26 enrolled
Treatment1 trial
Colorectal Adenocarcinoma1 trial
Advanced Soft-tissue Sarcoma1 trial
Molecular Profiling of Advanced Soft-tissue Sarcomas
Active, not recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 3·NCT03784014·603 enrolled
Neurofibromatosis1 trial
Prostate Cancer1 trial
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
Terminated·—·Phase 1/2·NCT00953576·11 enrolled
Small Cell Lung Cancer1 trial
Gastroesophageal Junction1 trial
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
Terminated·—·Phase 1/2·NCT01395537·13 enrolled
Capecitabine1 trial
Patients With Advanced Solid Tumors1 trial
Malignant Solid Neoplasms1 trial
Breast Neoplasms1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for lapatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]